Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 2/20 | 0.38 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.36 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.36 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.36 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.36 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.36 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.36 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.36 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.36 |
| ▸ | GABRP | O00591 | 1/20 | 0.36 |
| ▸ | GABRD | O14764 | 1/20 | 0.36 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.36 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.36 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.36 |
| ▸ | GABRE | P78334 | 1/20 | 0.36 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.36 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.36 |
| ▸ | GABRG3 | Q99928 | 1/20 | 0.36 |
| ▸ | GABRQ | Q9UN88 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4728474 | 0.75 | PDK1 (0.46) | CASP3PDK1PDK2GAACHEK1 | |
| SCHEMBL15902250 | 0.73 | PDK2 (0.36) | CASP3PDK2GABRA1GABRG2GABRB3 | |
| SCHEMBL4360026 | 0.72 | ALDH1A1 (0.41) | KDM4EALDH1A1 | |
| SCHEMBL22536418 | 0.71 | PDK1 (0.43) | PDK1PDK2ALDH1A1CYP11B2GAK | |
| SCHEMBL15901524 | 0.70 | GABRP (0.38) | CASP3GABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL13106344 | 0.68 | CASP3 (0.51) | CASP3ALDH1A1CYP11B2GAKRIPK2 | |
| SCHEMBL27359897 | 0.68 | CASP3 (0.42) | CASP3CYP11B2GAKRIPK2COQ8A | |
| SCHEMBL14737980 | 0.67 | CASP3 (0.41) | CASP3CYP11B2GAKRIPK2COQ8A | |
| SCHEMBL18306138 | 0.67 | CASP3 (0.40) | CASP3KDM4EALDH1A1GAACHEK1 | |
| SCHEMBL13106487 | 0.67 | CASP3 (0.41) | CASP3CYP11B2GAKRIPK2COQ8A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12012411-B2 | Viral replication inhibitors | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2024-06-18 | — | — | US | disclosed |
| US-20220106321-A1 | VIRAL REPLICATION INHIBITORS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2022-04-07 | — | — | US | disclosed |
| US-11279704-B2 | Viral replication inhibitors | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2022-03-22 | — | — | US | disclosed |
| CN-108440370-B | Inhibitors of viral replication | 鲁汶天主教大学 | 2021-07-30 | — | — | CN | disclosed |
| EP-3617192-A1 | VIRAL REPLICATION INHIBITORS | Katholieke Universiteit Leuven K.U. Leuven R&D (BE) | 2020-03-04 | — | — | EP | disclosed |
| US-10550123-B2 | Viral replication inhibitors | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) | 2020-02-04 | — | — | US | disclosed |
| US-20190337954-A1 | VIRAL REPLICATION INHIBITORS | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) | 2019-11-07 | — | — | US | disclosed |
| EP-2760831-B1 | VIRAL REPLICATION INHIBITORS | UNIV LEUVEN KATH (BE) | 2019-08-07 | — | — | EP | disclosed |
| US-20140213586-A1 | VIRAL REPLICATION INHIBITORS | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) | 2014-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140213586-A1 | VIRAL REPLICATION INHIBITORS | EIF2AK2, MAVS, ZC3HAV1 | CASP3 3373/4885PDK1 2919/4885PDK2 3258/4885 |
| US-11279704-B2 | Viral replication inhibitors | EIF2AK2, MAVS, ZC3HAV1 | CASP3 3373/4885PDK1 2919/4885PDK2 3258/4885 |
| US-20190337954-A1 | VIRAL REPLICATION INHIBITORS | EIF2AK2, MAVS, ZC3HAV1 | CASP3 3373/4885PDK1 2919/4885PDK2 3258/4885 |
| US-10550123-B2 | Viral replication inhibitors | EIF2AK2, MAVS, ZC3HAV1 | CASP3 3373/4885PDK1 2919/4885PDK2 3258/4885 |
| US-20220106321-A1 | VIRAL REPLICATION INHIBITORS | EIF2AK2, MAVS, ZC3HAV1 | CASP3 3373/4885PDK1 2919/4885PDK2 3258/4885 |
| US-12012411-B2 | Viral replication inhibitors | EIF2AK2, MAVS, ZC3HAV1 | CASP3 3373/4885PDK1 2919/4885PDK2 3258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.